This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification
NameTrofosfamide
Accession NumberDB12902
TypeSmall Molecule
GroupsInvestigational
Description

Trofosfamide has been used in trials studying the treatment of Ependymomas, Medulloblastomas, Sarcoma, Soft Tissue, Supratentorial PNETs, and Recurrent Brain Tumors.

Structure
Thumb
SynonymsNot Available
External IDs Not Available
Product Ingredients Not Available
ProductsNot Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNIIH64JRU6GJ0
CAS number22089-22-1
WeightAverage: 323.58
Monoisotopic: 322.0171479
Chemical FormulaC9H18Cl3N2O2P
InChI KeyUMKFEPPTGMDVMI-UHFFFAOYSA-N
InChI
InChI=1S/C9H18Cl3N2O2P/c10-2-6-13-5-1-9-16-17(13,15)14(7-3-11)8-4-12/h1-9H2
IUPAC Name
2-[bis(2-chloroethyl)amino]-3-(2-chloroethyl)-1,3,2lambda5-oxazaphosphinan-2-one
SMILES
ClCCN(CCCl)P1(=O)OCCCN1CCCl
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Trofosfamide.Approved
BCG vaccineThe therapeutic efficacy of Bcg can be decreased when used in combination with Trofosfamide.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Trofosfamide.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Trofosfamide.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Trofosfamide.Approved, Investigational
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Trofosfamide.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Trofosfamide.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Trofosfamide.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Trofosfamide.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Trofosfamide.Approved, Investigational
FingolimodTrofosfamide may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
G17DTThe risk or severity of adverse effects can be increased when Trofosfamide is combined with G17DT.Investigational
GI-5005The risk or severity of adverse effects can be increased when Trofosfamide is combined with GI-5005.Investigational
INGN 201The risk or severity of adverse effects can be increased when Trofosfamide is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Trofosfamide is combined with INGN 225.Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Trofosfamide is combined with Leflunomide.Approved, Investigational
NatalizumabThe risk or severity of adverse effects can be increased when Trofosfamide is combined with Natalizumab.Approved, Investigational
OleandrinAnvirzel may decrease the cardiotoxic activities of Trofosfamide.Experimental
OuabainOuabain may decrease the cardiotoxic activities of Trofosfamide.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Trofosfamide.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Trofosfamide.Approved, Investigational
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Trofosfamide is combined with Rabies vaccine.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Trofosfamide.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Trofosfamide is combined with CDX-110.Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Trofosfamide.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Trofosfamide.Approved
SRP 299The risk or severity of adverse effects can be increased when Trofosfamide is combined with SRP 299.Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Trofosfamide.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Trofosfamide is combined with TG4010.Investigational
TofacitinibTrofosfamide may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Trofosfamide.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesL01AA07 — Trofosfamide
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
2Unknown StatusTreatmentSoft Tissue Sarcoma (STS)1
2, 3Active Not RecruitingTreatmentEpendymomas / Medulloblastomas / Recurrent Brain Tumors / Supratentorial PNETs1
3RecruitingTreatmentSoft Tissue Sarcoma (STS)1
Properties
StateNot Available
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility12.0 mg/mLALOGPS
logP1.4ALOGPS
logP0.98ChemAxon
logS-1.4ALOGPS
pKa (Strongest Basic)0.15ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area32.78 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity72.72 m3·mol-1ChemAxon
Polarizability29.81 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted GC-MSPredicted GC-MS Spectrum - GC-MSNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as isofamides. These are oxazaphospholanes containing the isofamide skeleton. Isofamide is a heterocyclic compound made up of a 1,3,2-oxazaphospholane, where the phosphorus atom is part of a phosphodiamide group, and the oxazaphospholane is substituted by two haloalkyl chains.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassOxazaphosphinanes
Sub ClassIsofamides
Direct ParentIsofamides
Alternative ParentsNitrogen mustard compounds / Phosphoric monoester diamides / Oxacyclic compounds / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds / Organochlorides / Organic oxides / Hydrocarbon derivatives / Alkyl chlorides
SubstituentsIsofamide / Nitrogen mustard / Phosphoric monoester diamide / Organic phosphoric acid derivative / Organic phosphoric acid amide / Azacycle / Oxacycle / Hydrocarbon derivative / Organic oxide / Organooxygen compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External DescriptorsNot Available
Drug created on October 20, 2016 19:08 / Updated on September 01, 2017 12:26